KDR and neoplasm: In contrast, the pretreatment of the microvessel with SU-1498, an inhibitor to VEGF receptor 2 (VEGFR2, KDR/Flk-1), or pretreatment of the tumor cell with anti-VEGF antibodies not only decreased tumor cell adhesion compared to no pretreatments but also significantly reduced the adhesion enhanced by VEGF.